Clinical Trial Update: A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 bridging study evaluating liposomal cytarabine-daunorubicin for older patients with treatment-naive high-risk secondary acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Secondary Acute Myeloid Leukemia

Drugs mentioned

• liposomal cytarabine-daunorubicin (liposomal cytarabine-daunorubicin)

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: High-risk (Secondary) Acute Myeloid Leukemia | Phase 3 | Status: NOT_YET_RECRUITING